O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
Titel:
O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
Auteur:
Ducreux, M. Tabernero, J. Grothey, A. Arnold, D. O'Dwyer, P. Perdicchio, M. Assaf, Z. Das Thakur, M. Irahara, N. Tahiri, A. Schmoll, H. Van Cutsem, E. de Gramont, A.